[A25-19] Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2025
Project no.:
A25-19
Commission:
Commission awarded on 04.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Children and adolescents 2 years of age and older with active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis)
- Patients who have responded inadequately to previous therapy with a conventional synthetic disease-modifying antirheumatic drug: added benefit not proven
- Patients who have responded inadequately to previous therapy with a biological disease-modifying antirheumatic drug: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-19
| Project no. | Title | Status |
|---|---|---|
| A25-18 | Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-39 | Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |